# ZSKY

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zsky

- Industry: Healthcare Specialists
- Headquarters: Beijing, China
- Latest round: Series A (Nov 16, 2020)
- Investors on record: 5

## About

Established in 2018 and based in Beijing, China, ZSKY is a medical company that focuses on the research and development of individualized dendritic cell tumor vaccines (DC tumor vaccines).  It cooperated with Meiteni, NEC-OI, and other enterprises. In November 2020, ZSKY closed a pre-series A funding led by new investor Harmony Venture, with participation from other new investors Gongqingcheng Pengbo Investment Management, Leimerious, and Sichuan Development Holding.

ZSKY's business is the research, development, and production of the new generation of individualized DC tumor vaccines. It built an AI-based tumor neoantigen prediction system and functional validation system for the identification of tumor neoantigens. The company's products currently undergoing clinical trials include DC vaccines for middle and advanced malignant brain tumors, intestinal cancer, liver cancer, bile duct cancer, and pancreatic cancer.

## Funding rounds

- Series A, Nov 16, 2020 — Sichuan Development Holding, Harmony Venture, Leimerious, Gongqingcheng Pengbo Investment Management
- Angel, Sep 26, 2018 — Cowin Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel
- Sichuan Development Holding — Series A
- Harmony Venture (https://capitalatlas.ai/funds/harmony-venture) — Series A
- Leimerious — Series A
- Gongqingcheng Pengbo Investment Management (https://capitalatlas.ai/funds/gongqingcheng-pengbo-investment-management) — Series A